News | February 23, 2022
Biorchestra announces US$45 million series C fundraising
he financing was significantly oversubscribed with high demand from both existing and new investors.
he financing was significantly oversubscribed with high demand from both existing and new investors.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The transaction is expected to close in the first quarter of 2022
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
